Allogeneic

<!-- Name:DistributionId Value:8805324 --> <!--…
Read More...

<!-- Name:DistributionId Value:1000782840 --> <!--…
Read More...

Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for…
Read More...

-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million…
Read More...

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in…
Read More...

AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor…
Read More...

Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully…
Read More...

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of…
Read More...

-- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is…
Read More...

A novel chimeric antigen receptor (CAR) T-cell therapy…
Read More...